Navigation Links
PNNL chemist earns NIH New Innovator Award
Date:9/23/2009

RICHLAND, Wash. -- An analytical chemist at the Department of Energy's Pacific Northwest National Laboratory has been recognized with a National Institutes of Health Director's New Innovator Award. The award will support Wei-Jun Qian's drive to make new research and clinical diagnostic tools that are dramatically more sensitive, reliable and faster than current technologies.

The award, which comes with a $1.5 million, five-year grant, recognizes researchers early in their careers. Qian has been studying proteomics -- or the proteins that make organisms work -- at PNNL only since 2002 but has already published more than 60 scientific papers. NIH selected projects that show creativity and are considered high-risk ventures but with the potential to make a significant impact.

"This is great news for Wei-Jun and highlights the significant instrument development capabilities at PNNL," said Doug Ray, director of Fundamental & Computational Sciences at PNNL. "Not many DOE researchers earn such a prestigious NIH award. For his first grant, this is a major achievement."

Qian earned this honor for his proposal to increase the ability of research tools to detect diagnostic molecules in blood or tissue enough so they can replace conventional tools. When patients enter clinics now, they donate up to an ounce or two of blood so that multiple tests can be done. Each test -- for cholesterol, liver health, or cancer markers -- is generally performed seperately. A slate of 20 tests is far more labor and time intensive than just one. Qian would like to develop a single test for 20 diseases.

Research laboratories such as those found in EMSL, DOE's molecular sciences laboratory on the PNNL campus, have instruments called mass spectrometers that can identify hundreds of proteins and other molecules floating in a drop of that ounce of blood. Although much faster, the instruments aren't sensitive and accurate enough to compare with the clinical lab tests done one at a time.

"We are aiming to increase the sensitivity of our instrument so that we can detect proteins whose concentrations in blood are very low, and at the same time accurately measure their concentration for hundreds of different proteins -- perhaps up to a thousand," said Qian. "We hope this platform will lead to a paradigm change in how clinics do their testing."

Qian's plan will pull together tools that have been in development by the proteomics team at PNNL and EMSL for several years, but it will also require developing new technologies. The complete instrument identifies molecules in a sample such as blood by first separating them by size and shape and then measuring their mass as they flow past a detector.

Because different molecules can have the same mass, the technique breaks down molecules and identifies smaller pieces, which computer programs then recognize as belonging to certain molecules. Different molecules of the same mass will break into different pieces, much as the pieces of a 30-pound bike will be different from those of a 30-pound coffee table.

To improve the instruments' ability to detect rare molecules, Qian and his group have to increase the percentage of molecules in the sample that make it into the instrument at the beginning, as well as how many can be identified individually near the end. To improve the identification of individual molecules, Qian proposed that breaking down fragments into even more pieces will increase the resolving power of the detector.

"Eventually, the instrument will find a piece that is so unique we know which molecule it had to come from," Qian said.

Although such an instrument might replace current clinical tests someday, it will be equally valuable in the research laboratory, enabling scientists to screen many samples much faster than they are capable of now. This will cut down the time to find biomarkers -- proteins in the blood that indicate disease. For example, breast cancer researchers have identified almost 1000 proteins that show up or disappear, depending on the protein, when cancer is present. This technology could speed up the experiments needed to determine which of those are important for diagnosing illness.


'/>"/>

Contact: Mary Beckman
mary.beckman@pnl.gov
509-375-3688
DOE/Pacific Northwest National Laboratory
Source:Eurekalert  

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Computational actinide chemistry: Are we there yet?
3. Chemists get grip on slippery lipids
4. American Chemical Society calls green chemistry bill a smart step
5. Using green chemistry to deliver cutting-edge drugs
6. Good earth: Brown chemists show origin of soil-scented geosmin
7. Penn biochemist receives NIH New Innovators Award
8. Chemistry turns killer gas into potential cure
9. K-State chemistry professor to receive Masao Horiba award
10. Yale chemist receives NIH Young Investigator Award for antibody targeting
11. Biogeochemistry -- A window into the Earths ecological health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PNNL chemist earns NIH New Innovator Award
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , ... Inc. (ESI). Mr. Murray will bring valuable expertise ... experience in leading international business teams. As the National Division Leader, ... uphold Eurofins, status as the global leader in bio-analytical testing services. ... , , ...
(Date:12/8/2016)... 8, 2016 Oxford Gene Technology ... SureSeq™ NGS panel range with the launch of the SureSeq ... study of variants in familial hypercholesterolemia (FH). The panel delivers ... on a single small panel and allows customisation by ,mix ... all exons for LDLR , P C ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
Breaking Biology Technology: